HITK, paid $3 million for the rights to Zolpimist. They are also paying 15% royalties on sales. Given sales are insignificant, wouldn't it make sense to sell the license? I'm sure NVDL would let them so that they could get a partner that would spend the money needed to properly market the product. The problem with this is that they need to find someone willing to buy it. If their was truly value in the item it probably would have happened a while ago. No ones going to buy it, it has no value. The horse is dead, don't bet on it.
I never heard of any pharma that did not care about promoting its own safe and effective drug. Zolpimist is safe and is effective so what more would you want from any drug? If this company does not care about Zolpimist then they should sell the rights to it to some BIG pharma that will care. The insomnia market is huge in terms of any drug that is safe and effective means millions of dollars in pure profit.